Global Health Limited — Investor Meet, 09-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Medanta discussed the financial results for the quarter and nine-months ended December 31, 2025. Total income for the quarter surged 19% YoY to Rs.1,142.8 Cr. Core EBITDA (excluding Noida) grew 11% to Rs.281.4 Cr, achieving 25.4% margins. Consolidated EBITDA stood at Rs.249.4 Cr (21.8% margins), reflecting initial losses from the new Noida facility, which posted Rs.34.3 Cr revenue against an Rs.32 Cr EBITDA loss. Adjusted profit for the quarter reached Rs.122.4 Cr, excluding a one-time statutory impact. International patient revenue jumped 30% to Rs.70.3 Cr. ARPOB climbed 10% to Rs.67,361, with occupancy around 59%.

Management expressed confidence in Noida's ramp-up, adding 102 beds and 9 OTs. Lucknow earned JCI accreditation. Developing hospitals (excluding Noida) reported strong 31.7% margins, with Lucknow's margins expanding over 150bps. Projected ARPOB growth is 5-7% annually. Net cash stands at Rs.600 Cr. FY27 CAPEX is estimated below Rs.500 Cr. Management acknowledged industry talent acquisition and ongoing commercial insurer negotiations.